TuHURA Biosciences (HURA)

• Market cap: $117M
• 1 day: -0.95%
• 5 days: 13.66%
• 1 month: 84.07%
• 3 months: 139.08%
• 6 months: -14.4%
• Year to date: 177.52%
• 1 year: -14.05%
• 5 years: -99.94%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Employees: 19